Other studies document that quantification of ERCC1 (excision repair cross-complementation group 1) or cyclophilin 3 expression in iCTCs might be used to monitor platinum resistance and post-therapeutic outcome of ovarian cancer patients [7,23]. Here, ERCC1 is linked to ovarian cancer.